close
Choose Your Site
Global
Social Media
Views: 0 Author: Site Editor Publish Time: 2026-06-05 Origin: Site
Echinacea Extract-Cichoric Acid is a standardized botanical extract manufactured by World-Way Biotech from the aerial parts of Echinacea purpurea (L.) Moench using a scientifically optimized water-ethanol co-solvent extraction process. The product employs cichoric acid as its primary quality control marker, quantified via HPLC (High-Performance Liquid Chromatography) at a specification of 2%-4%, with total polyphenol content additionally standardized at 4% (UV spectrophotometry). The product presents as a brown to yellow-green fine powder and stands as a globally significant functional ingredient in the immune health sector.
As the core component of World-Way’s Dephcynex® Compound Echinacea Powder, this ingredient overcomes the industry limitation of single-target immune enhancement with limited efficacy. Through strategic combination with Astragalus membranaceus extract (containing astragaloside IV) and ginger extract (containing gingerols), it achieves multi-target, multi-pathway, multi-level comprehensive immune defense upgrading—from immune organs to immune cells to immune molecules. The product’s manufacturing complies with KOSHER, HALAL, HACCP, ISO 9001, and FSSC 22000 international certifications, with standard packaging of 25 kg per drum under airtight, low-humidity, light-protected storage conditions.
Echinacea purpurea (L.) Moench, commonly known as purple coneflower, is a perennial herbaceous plant in the Asteraceae family, native to the central Great Plains of North America and now widely cultivated across Europe and China. Plants reach 60-150 cm in height, with erect, coarse-haired stems, alternate ovate to ovate-lanceolate serrated leaves, and terminal solitary capitulum inflorescences. The ray florets are conspicuously purplish-red to pink-purple, while the densely packed disc florets form the characteristic raised copper-orange conical center (hence the common name coneflower). Among the nine recognized Echinacea species, E. purpurea, E. angustifolia, and E. pallida are the three principal species cultivated for commercial medicinal use, with E. purpurea being the preferred choice for the global extract industry due to its abundant aerial biomass and high bioactive compound content.
World-Way sources Echinacea purpurea aerial parts (stems, leaves, and flowers) from standardized cultivation. Harvesting is timed to the full flowering stage (70%-80% bloom rate), when cichoric acid and polyphenol accumulation in the plant tissue reaches peak levels. Freshly harvested material undergoes rapid drying at controlled temperatures (40-50°C) to minimize enzymatic oxidative degradation and preserve cichoric acid’s chemical stability. Dried material is then milled to the appropriate particle size before entering the standardized extraction workflow.
Echinacea holds one of the longest documented histories of medicinal use among Native American botanicals. Great Plains tribes—including the Lakota and Cheyenne—extensively utilized echinacea for treating snakebites, wound infections, toothaches, sore throats, and cold-related fevers. In the late 19th century, Swiss physician Alfred Vogel introduced echinacea to Europe, after which it rapidly became one of the best-selling immune-enhancing herbal medicines in Western markets. The European Medicines Agency (EMA) monograph officially recognizes echinacea extract for its traditional use in alleviating common cold symptoms and confirms its safety for long-term use. Modern research has further identified cichoric acid as the signature bioactive compound responsible for echinacea’s immunomodulatory and antiviral activities.
Cichoric acid (2,3-dicaffeoyltartaric acid, C₂₂H₁₈O₁₂, MW 474.37) is the most abundant caffeic acid derivative in Echinacea purpurea and the core signature compound responsible for its immunomodulatory and antiviral activities. Cichoric acid content in echinacea aerial parts ranges from 1.5% to 4.0% (dry weight), with 70%-80% aqueous ethanol extraction providing optimal recovery efficiency. World-Way employs HPLC for precise quantification of cichoric acid content, ensuring batch-to-batch specification consistency (2%-4%). Cichoric acid exerts its antiviral barrier function at the earliest stage of infection by inhibiting viral hemagglutinin (HA) activity, thereby blocking virus-host cell receptor binding. Concurrently, it promotes immune cell activation and cytokine secretion through modulation of immune-related signaling pathways, achieving multi-dimensional immune enhancement.
Beyond cichoric acid, echinacea extract naturally contains a rich array of other polyphenolic compounds (total polyphenols ≥ 4%), including chlorogenic acid, caffeic acid, echinacoside (primarily in E. angustifolia roots), and various flavonoids. These polyphenols form a natural multi-target synergistic matrix with cichoric acid: chlorogenic acid provides additional antioxidant and anti-inflammatory support; caffeic acid enhances hyaluronidase inhibition to maintain tissue barrier integrity; and flavonoids modulate macrophage polarization to preserve immune homeostasis. This full-spectrum polyphenol profile ensures that the overall immune efficacy of echinacea extract substantially exceeds the simple additive effect of its individual compounds.
World-Way has developed the Dephcynex® compound formulation based on a dual framework of TCM theory and modern pharmacology, combining echinacea extract (cichoric acid 2%-4%) with Astragalus membranaceus extract (astragaloside IV) and ginger extract (gingerols). Astragaloside IV significantly increases peritoneal macrophage phagocytic rate and phagocytic index, while markedly elevating immune organ indices (spleen and thymus), fortifying immune defenses at the organ level. Gingerols provide warming and cold-dispersing adjuvant effects, improving the formulation’s overall medicinal balance. The three components operate at distinct immune levels: echinacea handles frontline antiviral defense and immune signaling activation; astragalus handles logistics—expanding the immune cell arsenal; and ginger elevates overall systemic readiness.
In 2009, the research group led by Stephan Pleschka at Justus Liebig University Giessen published an in vitro study in Virology Journal demonstrating that echinacea extract directly and dose-dependently inhibits influenza virus hemagglutination activity, preventing the virus from agglutinating erythrocytes via hemagglutinin protein—the initial step of influenza virus host cell invasion. The study encompassed testing against seasonal strains (H3N2), highly pathogenic avian influenza strains (H5N1, H7N7), and swine-origin pandemic strains (H1N1), with echinacea extract exhibiting potent inhibitory potential against all tested strains. This broad-spectrum antiviral property confers unique clinical value for echinacea extract in influenza prevention and early intervention.
A 2022 clinical study published by Emil Kolev and colleagues provided high-quality human evidence for echinacea extract’s immune-protective effects. The study systematically evaluated respiratory tract infection (RTI) virus detection rates, with clear findings: for coronaviruses, the echinacea group showed significantly reduced detection risk (OR=0.42, RR=0.517, p=0.046); for SARS-CoV-2 specifically, the risk reduction was even more pronounced (OR=0.31, RR=0.369, p=0.03). In practical terms, echinacea extract reduced coronavirus infection risk by approximately 48% and SARS-CoV-2 infection risk by approximately 63%. These data establish echinacea extract as a clinically validated, statistically significant preventive natural intervention against respiratory viral infections.
The immunomodulatory mechanism of echinacea extract comprises an intricate multi-target network. At the innate immunity level, echinacea polysaccharides and glycoprotein components activate Toll-like receptors (TLR2/TLR4), promoting macrophage and dendritic cell maturation and activation. At the adaptive immunity level, cichoric acid enhances CD4⁺ T cell proliferation and differentiation, promoting Th1-type immune response maturation, enabling the body to establish effective immune defenses more rapidly upon viral challenge. Additionally, echinacea extract upregulates natural killer (NK) cell cytotoxic activity and enhances antibody-dependent cell-mediated cytotoxicity (ADCC), achieving comprehensive clearance capacity against virus-infected cells.
The product serves four primary application domains. Immune-enhancing dietary supplements: as the core active ingredient in capsules, tablets, or powders for daily immune maintenance targeting cold-prone and immunocompromised populations. Early cold intervention products: leveraging its broad-spectrum antiviral properties and clinically validated data, these interceptive products are designed for use at the earliest onset of cold symptoms, offering competitive differentiation from classical immune ingredients such as vitamin C and zinc. Compound immune formulations: as the core component of Dephcynex®, providing more comprehensive multi-target immune support than single-echinacea products through scientific pairing with astragalus and ginger. Respiratory health functional foods: innovative convenient formats such as immune lollipops, immune effervescent tablets, and immune ready-to-drink shots featuring echinacea extract.
Echinacea is one of the largest immune-health botanical extract categories in the global market. According to Industry ARC data, the global echinacea extract market was valued at approximately USD 280 million in 2023 and is projected to reach USD 410 million by 2028 (CAGR 7.9%). North America and Europe represent the largest consumer markets, while the Asia-Pacific region (particularly China) is the fastest-growing. World-Way’s Echinacea Extract-Cichoric Acid holds core competitive advantages globally: first, high standardization—the 2%-4% cichoric acid HPLC specification substantially exceeds industry averages, ensuring batch-to-batch efficacy consistency. Second, formulation upgrade—Dephcynex® elevates echinacea from solo operation to combined-arms synergy, carving out a differentiated blue ocean within the red ocean of immune supplements. Third, comprehensive certification—FSSC 22000, KOSHER, HALAL, and other international certifications enable barrier-free entry into all major global markets.
Echinacea Extract-Cichoric Acid is supplied as a fine powder with a recommended daily dosage of 500 mg (Dephcynex® compound powder). The product exhibits excellent flowability and fillability for capsule manufacturing, making it ideally suited as a core ingredient for hard capsule immune supplements. It can also be combined with other immune-supporting ingredients (vitamin C, vitamin D3, zinc, elderberry extract, etc.) for diverse innovative formulations. Storage requires airtight, low-temperature, light-protected conditions to ensure the chemical stability of cichoric acid and other polyphenolic constituents.
Frequent cold sufferers and infection-prone individuals: those experiencing more than three colds per year with slow recovery represent echinacea extract’s core target consumer segment. Individuals with delayed recovery: those with prolonged post-infection recovery, easy recurrence, and delayed wound healing, indicating a need for exogenous immune system support. Chronically fatigued and sub-healthy populations: office workers and students experiencing persistent fatigue (unrelieved even with rest), mental lethargy, and poor concentration, often accompanied by compromised immunity. Individuals with immune-related skin conditions: consumers presenting with acne, eczema, dermatitis, and other immune-mediated skin issues may benefit from echinacea’s modulation of Th1/Th2 immune balance. Seasonal protection seekers: general consumers requiring additional immune support during autumn-winter seasonal transitions and peak influenza periods.
Echinacea extract is generally well-tolerated with a favorable safety profile. According to the EMA monograph, long-term use at the recommended dosage (500 mg/day) is safe for adults. Individuals with known allergies to Asteraceae family plants (ragweed, chrysanthemum, marigold) should exercise caution due to potential cross-reactivity. Patients with autoimmune conditions (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis) should use under medical supervision, as echinacea’s immune-stimulating effects could theoretically exacerbate autoimmune responses. Pregnant and breastfeeding women should consult a healthcare practitioner before use.
The production of echinacea extract-cichoric acid follows a rigorously controlled manufacturing process. Echinacea purpurea aerial parts harvested at peak flowering are dried at 40-50°C and milled to 20-40 mesh particle size. Extraction employs a 70% ethanol/30% water (v/v) solvent system at 50-60°C for optimized cichoric acid recovery while minimizing co-extraction of chlorophyll and waxes. The extract undergoes vacuum concentration (<60°C, -0.08 MPa) followed by spray drying with maltodextrin carrier to produce a free-flowing powder with standardized cichoric acid content. Quality control includes HPLC quantification of cichoric acid (specification: 2.0%-4.0%), UV spectrophotometric determination of total polyphenols (≥4.0%), loss on drying (≤5.0%), heavy metal analysis (Pb ≤ 1.0 ppm, As ≤ 1.0 ppm, Hg ≤ 0.1 ppm, Cd ≤ 0.5 ppm), microbiological testing (total plate count ≤ 10,000 CFU/g, yeasts and molds ≤ 100 CFU/g, E. coli and Salmonella: absent), and pesticide residue screening. Each production batch is accompanied by a Certificate of Analysis (CoA) documenting all quality parameters. The product is packaged in 25 kg food-grade HDPE drums with double-layer PE liner bags under nitrogen flush to prevent oxidation, with recommended storage at 15-25°C, relative humidity <60%, protected from light for a shelf life of 24 months from the date of manufacture.
In the crowded immune health ingredient landscape, echinacea extract-cichoric acid offers distinct advantages over competing ingredients. Echinacea angustifolia root extract—the other major commercial echinacea species—is richer in alkylamides but contains significantly less cichoric acid (<1%), making it less suitable for standardized antiviral applications. Beta-glucans (from yeast or mushroom sources) primarily activate innate immunity through dectin-1 receptor binding, but lack the direct antiviral hemagglutination inhibition demonstrated by echinacea’s cichoric acid. Astragalus polysaccharides excel at enhancing macrophage phagocytosis and immune organ indices, which is precisely why World-Way combines astragalus with echinacea in Dephcynex®—rather than positioning them as competitors, they function as complementary partners addressing different immunological tiers. Vitamin C and zinc, while widely used, operate through fundamentally different mechanisms (antioxidant protection and enzyme cofactor function, respectively) and do not provide the direct antiviral activity or multi-level immune cell activation characteristic of echinacea extract. This mechanistic complementarity positions echinacea extract-cichoric acid not as a replacement for existing immune ingredients, but as a synergistic addition that fills the specific gap of broad-spectrum antiviral defense at the earliest stage of viral challenge.
Echinacea Extract-Cichoric Acid represents a strategically important product in World-Way Biotech’s immune health ingredient portfolio. It builds a foundation of quality trust through its 2%-4% cichoric acid HPLC standardization, provides scientific persuasiveness through broad-spectrum antiviral activity data spanning from seasonal influenza to SARS-CoV-2, and achieves functional leapfrogging from single-point immune enhancement to comprehensive immune defense through the multi-target synergistic strategy of the Dephcynex® compound formulation.
In the global post-pandemic era, consumer attention to immune health has shifted from emergency response to sustained daily maintenance. Echinacea Extract-Cichoric Acid—armed with clinically validated respiratory infection prevention efficacy, millennia of trust inherited from Native American herbal wisdom, and product quality conforming to the highest global certification standards—stands at the golden window of opportunity in the immune health ingredient market. It is not merely a premium choice for immune supplement formulation but a natural tool empowering global consumers to transition from passive treatment to proactive defense.
